Shopping Cart
Remove All
Your shopping cart is currently empty
(R,R)-LRRK2-IN-7 is an isomer of LRRK2-IN-7, a potent and selective LRRK2 kinase inhibitor with CNS penetrance. It exhibits an IC50 of 0.9 nM and demonstrates over 1000-fold selectivity compared to other kinases, ion channels, and CYP enzymes.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | (R,R)-LRRK2-IN-7 is an isomer of LRRK2-IN-7, a potent and selective LRRK2 kinase inhibitor with CNS penetrance. It exhibits an IC50 of 0.9 nM and demonstrates over 1000-fold selectivity compared to other kinases, ion channels, and CYP enzymes. |
| In vitro | LRRK2-IN-7 (compound 25) is both a substrate for Breast Cancer Resistance Protein (BCRP) in mice and humans and an effective human BCRP inhibitor with a BCRP IC50 of 0.12 μM. |
| In vivo | In a 7-day dose-limiting toxicity study on rats, LRRK2-IN-7 (compound 25) was well tolerated at doses up to 100 mg/kg administered once daily (AUC tot = 330 μM·h). During an acute (2-hour) PK/PD study in rats, LRRK2-IN-7 (compound 25) demonstrated a dose-dependent reduction of LRRK2 pS935 in the rat striatum, with an EC50 of 0.18 nM. |
| Molecular Weight | 414.50 |
| Formula | C24H26N6O |
| Cas No. | 2307277-92-3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.